Abstract-For radionuclides such as plutonium and americium, detection of removable activity in the nose (i.e., nasal swab measurements) are frequently used to determine whether follow-up bioassay measurements are warranted following a potential intake. For this paper, the authors analyzed 429 nasal swab measurements taken following incidents or suspicious circumstances (such as an air monitor alarming) at Los Alamos National Laboratory (LANL) for which the dose was later evaluated using in vitro bioassay. Nasal swab measurements were found to be very poor predictors of dose and should not be used as such in the field. However, nasal swab measurements can be indicative of whether a reliably detectable committed effective dose (CED) occurred. About 14% of nasal swab measurements between 1.25 and 16.7 Bq corresponded to CEDs greater than 1 mSv, so in general, positive nasal swabs always indicate that follow-up bioassay should be performed (positive nasal swabs less than 1.25 Bq are considered separately). This probability increased significantly for nasal swabs greater than 16.7 Bq. Only about 3% of nasal swabs with no detectable activity (NDA) corresponded to reliably detectable CEDs. A nasal swab with NDA is therefore necessary, but not sufficient, to negate the need for a follow-up bioassay if it was collected following other workplace indicators of a potential intake. Health Phys. 112(5): 465-469; 2017 
INTRODUCTION
IN FACILITIES where workers are considered to be at risk of inhaling plutonium (Pu) and/or americium (Am), significant engineering controls have been implemented to prevent this from happening. Failure of these controls is indicated by a number of "triggers," such as an alarm from a continuous air monitor (CAM), an elevated count rate on a laboratory surface, personnel contamination, or an obviously abnormal situation such as a spill or a fire, which could indicate the potential for an intake. On their own, these triggers rarely constitute strong evidence that an inhalation has occurred and must therefore be combined with a host of other factors to determine whether a particular worker is at risk. Historically, nasal swabs have been used as triggers to determine whether further investigation was warranted, and as such they were administered to Pu and Am workers on a daily basis. In modern times, as inhalations have become less common and instruments have become more sensitive, routine nasal swabs have been largely replaced by CAMs and fixed air samplers (FASs) for triggering investigation of a possible inhalation. Instead, nasal swabs are typically performed in response to an abnormal situation and are used in conjunction with a variety of other factors to determine whether a measurable committed effective dose (CED) is likely to have occurred.
Many (perhaps most) nasal swabs with no detectable activity are taken to verify that no intake occurred following another workplace indicator. However, positive nasal swabs can always be presumed to coincide with a "real" incident. For that reason, nasal swabs with no detectable activity (NDA) cannot be assumed to have the same relationship to dose as low activity positive nasal swabs. Similarly, positive nasal swabs less than 1.25 Bq do not constitute incidents in the absence of any other trigger or abnormal situation at Los Alamos National Laboratory (LANL), and the decision to order bioassay measurements is left to the judgment of the radiation protection professional. It follows that the cases in this activity range are likely incomplete and biased toward more serious incidents. This is resolved by focusing the analysis on nasal swab measurements greater than 1.25 Bq and considering lower activity nasal swab measurements separately. This paper revisits a similar analysis published by the LANL Internal Dosimetry group in 2007 (Guilmette et al. 2007 ). In the original paper, 15 y of nasal swab data collected at LANL were compared with the committed effective doses assessed using Bayesian dose assessment methods. That paper reported a loose correlation (R = 0.437) between the nasal swab activity and the CED when considering *Los Alamos National Laboratory, Los Alamos, NM 87545.
only incidents involving 239 Pu in which both were positive. However, because the correlation was so weak and the variation so large, it was not clear how this finding should be applied in the field.
The analysis in this paper considers an expanded set of LANL bioassay nasal swab data with the goal of producing a result that could be more useful in the field. The expanded dataset includes incidents involving 238 Pu and 241 Am (which have very similar committed effective dose coefficients) as well as positive nasal swab measurements in which the CED was zero. A linear fit was performed on the data to determine if the expanded dataset revealed an improved correlation between nasal swab measurement and CED. In addition, the dataset was analyzed to determine the relationship between nasal swab measurements and the probability of a CED greater than 1 mSv.
METHODS
Nasal swabs are performed on LANL workers whenever there is an indication that a release of plutonium or americium may have occurred; for example, whenever an employee is present without respiratory protection when a continuous air monitor alarms or when contamination is found on the employee's chest, shoulders, neck, head, or respirator. The nasal swab technique can be summarized as follows. For each nostril, a wet cotton swab is inserted and swabbed in a circular motion. The two swabs are counted separately using liquid scintillation, and the results are reported to the operational health physicist. A more detailed description of the methodology for collecting nasal swab samples and evaluating dose can be found in the original paper on interpreting LANL nasal swab measurements (Guilmette et al. 2007 ).
While nasal swab activity might be expected to be a better predictor of intake magnitude than dose, this relationship is of little practical interest. Because the purpose of this analysis was to identify relationships that should be useful in the field, the relationship between nasal swab activity and committed effective dose was analyzed. The committed effective dose coefficients for 5 mm AMAD particles for 241 Am, 238 Pu, and 239 Pu of solubility Type M (medium) and Type S (slow) are shown in Table 1 . It is evident that, for these isotopes, the CED per unit of intake is very similar (within about 20%) for a given particle size and solubility class. This is dwarfed by the variation as a function of particle size, solubility class, and relationship between nasal swab and intake. For that reason, nasal swabs for all three isotopes were included in the analysis.
The data for this analysis were gathered from the LANL bioassay database. Every incident that resulted in a nasal swab and subsequent dose analysis using urine bioassay was extracted from this database. The dataset includes incidents that occurred between 1973 and 2015. The CEDs were calculated using only urine bioassay measurements. These were performed using alpha spectroscopy and, for 239 Pu intakes, mass spectrometry.
For each entry, the data included the date when the nasal swab was performed, the isotope of concern in the incident, the number of counts from nasal swabs of the left and right nostrils, and the intake and CED that were ultimately assigned to the incident. In most people, the nasal airways regularly congest and decongest in a way that keeps the total nasal airway resistance constant (Gilbert and Rosenwasser 1987) . In addition, anatomical variations result in many people having less airway resistance in one nostril compared to the other (Guilmette et al. 1989) . In order to negate these natural variations, only the sum of the measurements in each nostril were considered for the analysis.
The dataset contained 318 entries that had no detectable activity (NDA) on the nasal swab measurement (the MDA is between 0.28 and 0.41 Bq, depending on count time), 58 cases that measured positive activity less than 1.25 Bq, and 53 cases that had nasal swab measurements greater than 1.25 Bq. The calculated CEDs ranged from 0 to 870 mSv, and the positive nasal swab measurements ranged from 0.033 to 2,783 Bq. The nasal swab data were analyzed in two ways. First, a linear regression was performed on the data in order to look for a correlation between the magnitude of nasal swab measurements and the magnitude of CED. Unlike nasal swab measurements greater than 1.25 Bq, many of the smaller nasal swabs that measured NDA were likely performed in response to "false alarms" where no release actually occurred, while many positive measurements less than 1.25 Bq were likely not followed up with bioassay measurements. To help eliminate these biases, only cases that resulted in positive nasal swabs greater than 1.25 Bq were included in the linear fit.
The second analysis explored whether the magnitude of a nasal swab measurement was related to the probability that a CED occurred that would justify ordering urine bioassay measurements in response to the nasal count. The threshold chosen was 1 mSv CED, as this is roughly the smallest CED of 239 Pu that was reliably detectable in 1973. Of the positive nasal swabs, 20 corresponded to "reliably detectable" CEDs (>1 mSv). Of the NDA nasal swabs, nine corresponded to reliably detectable CEDs (>1 mSv). 
RESULTS
Following the Guilmette et al. paper (2007) , the data were first fit to a linear curve. The largest count and committed effective dose were excluded because of the dominant effect they had on the outcome of the fit. For clarity, Fig. 1 contains the data and fit on a log-log scale. The fitted line was:
where D is the CED and A is the sum of the measured Bq from both nostrils. The correlation coefficient, R, was 0.22, suggesting only weak correlation between the nasal swabs and the CED. In contrast, the Guilmette paper (2007) found a correlation coefficient of 0.437. The difference is almost entirely due to the inclusion of 238 Pu intakes, which tend to cause larger CEDs due to 238 Pu's higher specific activity, in this analysis. However, regardless of which dataset is used, the value of the correlation coefficient is strongly dependent on the largest CEDs included in the dataset. Looking at the fitted line, it is tempting to think that it might be significantly improved by excluding a particular category of data; e.g., the smallest or largest activity nasal swab measurements or the smallest or largest doses. However, all of these were tried, and none significantly improved the correlation. The exact value of the correlation coefficient is therefore uncertain, although one can be confident that it is small. Fig. 2 shows the data and fit plotted on a linear scale, which emphasizes the significance of the deviations from the fit.
It follows that nasal swab measurements are a poor predictor of CED and that this fit line should not be used in a field. Nonetheless, it was possible to extract some useful insights from the dataset. As discussed above, the CED estimates for each entry in the data set were divided into those that were reliably detectable CEDs (>1 mSv) and those that were not (<1 mSv). These data were used to calculate the fraction of cases with reliably detectable CEDs within certain nasal swab count ranges. The results are as follows: for nasal swabs with NDA, between 1 and 1.25 Bq, between 1.25 and 16.7 Bq, between 16.7 Bq and 33.3 Bq, and between 33.3 Bq and 166.7 Bq, about 3%, 7%, 14%, 57%, and 71% of cases corresponded to reliably detectable CEDs, respectively. The exact values are shown in Fig. 3 .
DISCUSSION
In order to accurately predict committed effective doses based on nasal swabs, a model would also need to include (at least) information about the aerosol size distribution, particle solubility, how the material was deposited in the nose (e.g., by inhalation or by a hand or finger), whether the individual is a nose or mouth breather, and whether the individual had blown his/her nose prior to the event. In practice, little if any of this information is available for most events.
Given the small dataset, large measurement uncertainties, and lack of information about confounding factors, it is therefore not surprising that the analysis showed very little correlation between the magnitude of the nasal swab measurement and the magnitude of the CED. A closer inspection of the data emphasizes the potential pitfalls of using the linear fit to predict doses. Consider the nasal swab measurement of 20.7 Bq. According to the fit, this should predict a CED of about 9.48 mSv. In fact, the CED associated with that measurement was 187 mSv. On the other extreme, consider the case with a nasal swab measurement of 102.2 Bq. The fit predicts that this measurement should be associated with a CED of 24.5 mSv. This CED would exceed the Laboratory limit and likely result in a major investigation. However, the actual CED was calculated as a mere 0.06 mSv-so low that one could not say with any confidence that an intake occurred at all.
Although the nasal swab measurements are not strongly correlated with the magnitude of CEDs, they are strongly correlated with the probability that a measurable CED of any sort has occurred. This analysis has the virtue of providing potentially useful information without encouraging overconfidence. About 3% of NDA nasal swabs corresponded to measurable CEDs. When conducted following a suspected false alarm, a NDA nasal swab is necessary, but not sufficient, for the responsible radiation protection professional to conclude that a followup bioassay is not necessary. In contrast, about 14% of nasal swabs between 1.25 and 16.7 Bq corresponded to measurable CEDs. This suggests that nasal swab measurements greater than 1.25 Bq always indicate that follow-up bioassay measurements should be ordered. Finally, nasal swabs greater than about 16.7 Bq were significantly more likely to correspond with measurable CEDs. However, the radiation protection professional and the employee should be aware that these do not necessarily correspond to larger doses.
About 7% of positive cases less than 1.25 Bq corresponded to measurable doses. However, it is not clear how this figure should be interpreted, as it is as much a reflection of the radiation protection professional's judgment as it is of the significance of the measurement. In particular, it is impossible to determine how many of these measurements were not reported and, of those, what fraction might have corresponded to measurable CEDs. However, one may safely assume that nasal swab measurements that coincided with other positive indicators were more likely to be referred for follow-up bioassay than those that did not. It is also reasonable to assume that a small positive nasal swab measurement is more likely to correspond to a measurable CED than a NDA nasal swab. This suggests that the true fraction of cases corresponding to measurable CEDs is between 3% (the value for NDA nasal swabs) and 7% (the observed value). This range of probabilities may justify continued reliance on the discretion of the radiation safety professional to decide whether bioassay should be ordered.
CONCLUSION
This paper examined nasal swab data from the LANL bioassay database with the goals of investigating the predictive value of nasal swab measurements on committed effective dose and on the probability that a reliably detectable CED may have occurred. The database contained 111 positive nasal swab measurements and 318 NDA nasal swab measurements of Am. Nasal swab measurements were found to be very poor predictors of CED and should not be used as such in the field. Only about 3% of nasal swabs with NDA corresponded to reliably detectable CEDs. A nasal swab with NDA is therefore necessary, but not sufficient, to negate the need for a follow-up bioassay when conducted following a suspected false alarm. About 7% of positive nasal swab measurements less than 1.25 Bq corresponded to measurable (>1 mSv) CEDs, but this is biased by the fact that bioassays are not required for measurements in this range. The true value is likely between 3% and 7%, which justifies relying on the discretion of the radiation safety officer to decide whether bioassay should be ordered. About 14% of nasal swab measurements between 1.25 and 16.7 Bq corresponded to measurable CEDs, so nasal swabs in this range always indicate that follow-up bioassay should be performed. The probability that a measurable CED occurred increased significantly for nasal swabs greater than 16.7 Bq.
